Palazestrant vs Vepdegestrant
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline
Palazestrant
Developed by Olema Pharmaceuticals, Inc.
NCT04505826 · Phase 1/2 · completed
The study was nonrandomized, unblinded, and single-arm, with participants receiving OP-1250 at sequential dose levels and no placebo or active comparator. Its results were descriptive rather than a formal comparative test: dose-limiting toxicities were 0/42 during dose escalation, while confirmed partial responses included 4/62 participants at 120 mg once daily; therefore, the primary outcomes were not formally met or missed against a control.
Next expected readout: December 2027 · NCT05508906 (registry estimate)
No aligned efficacy figure on record for this race.
Vepdegestrant · Veppanu
Marketed by Rigel Pharmaceuticals and partners
NCT05654623 · Phase 3 · active, not recruiting
Randomized and controlled against fulvestrant, with progression read by blinded independent central review, but open-label. Of its two primary comparisons, progression-free survival was significantly longer in patients with ESR1 mutations (5.0 vs 2.1 months) but not in all randomized patients (3.8 vs 3.6 months, P=0.07), so the result is mixed.
Next expected readout: December 2026 · NCT05909397 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1- All Randomized Participants (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)); PFS by BICR Assessment Per RECIST v1.1-Participants With ESR1 Mutation (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)): PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025). (mixed)
Result source: NCT05654623
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Palazestrant | Vepdegestrant |
|---|---|---|
| PFS, median | —Trial running · NCT06016738 | 3.7 vs 3.6vs FulvestrantNCT056546231 other result
|
| OS, median | —Trial running · NCT06016738 | —Trial running · NCT05909397 |
| ORR | —Trial running · NCT06016738 | 10.9% vs 3.6%vs FulvestrantNCT05654623 |
| Clinical benefit rate | —Trial running · NCT06016738 | 34.3% vs 28.7%vs FulvestrantNCT05654623 |
PFS, median
- Palazestrant
- —Trial running · NCT06016738
- Vepdegestrant
- 3.7 vs 3.6vs FulvestrantNCT05654623
1 other result
- 5 vs 2.1 NCT05654623
OS, median
- Palazestrant
- —Trial running · NCT06016738
- Vepdegestrant
- —Trial running · NCT05909397
ORR
- Palazestrant
- —Trial running · NCT06016738
- Vepdegestrant
- 10.9% vs 3.6%vs FulvestrantNCT05654623
Clinical benefit rate
- Palazestrant
- —Trial running · NCT06016738
- Vepdegestrant
- 34.3% vs 28.7%vs FulvestrantNCT05654623
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Palazestrant: 3 of 4 rows · Vepdegestrant: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Palazestrant | Vepdegestrant |
|---|---|---|
| Dropout rate | —300 mg QDa NCT04505826 · Phase 1/2 show 14 more results0%300 mg QD NCT04505826 · Phase 1/2 —210 mg QD NCT04505826 · Phase 1/2 0%210 mg QD NCT04505826 · Phase 1/2 —150 mg QD NCT04505826 · Phase 1/2 0%150 mg QD NCT04505826 · Phase 1/2 —120 mg QD NCT04505826 · Phase 1/2 —120 mg QD NCT04505826 · Phase 1/2 0%120 mg QD NCT04505826 · Phase 1/2 —90 mg QD NCT04505826 · Phase 1/2 0%90 mg QD NCT04505826 · Phase 1/2 —60 mg QD NCT04505826 · Phase 1/2 0%60 mg QD NCT04505826 · Phase 1/2 —30 mg QD NCT04505826 · Phase 1/2 0%30 mg QD NCT04505826 · Phase 1/2 | 7.8%a NCT05549505 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —300 mg QDa NCT04505826 · Phase 1/2 show 14 more results—300 mg QD NCT04505826 · Phase 1/2 —210 mg QD NCT04505826 · Phase 1/2 —210 mg QD NCT04505826 · Phase 1/2 —150 mg QD NCT04505826 · Phase 1/2 —150 mg QD NCT04505826 · Phase 1/2 —120 mg QD NCT04505826 · Phase 1/2 —120 mg QD NCT04505826 · Phase 1/2 —120 mg QD NCT04505826 · Phase 1/2 —90 mg QD NCT04505826 · Phase 1/2 —90 mg QD NCT04505826 · Phase 1/2 —60 mg QD NCT04505826 · Phase 1/2 —60 mg QD NCT04505826 · Phase 1/2 —30 mg QD NCT04505826 · Phase 1/2 —30 mg QD NCT04505826 · Phase 1/2 | —a NCT05549505 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 28.6%300 mg QDa NCT04505826 · Phase 1/2 show 14 more results—300 mg QD NCT04505826 · Phase 1/2 28.6%210 mg QD NCT04505826 · Phase 1/2 —210 mg QD NCT04505826 · Phase 1/2 40%150 mg QD NCT04505826 · Phase 1/2 —150 mg QD NCT04505826 · Phase 1/2 19.3%120 mg QD NCT04505826 · Phase 1/2 57.1%120 mg QD NCT04505826 · Phase 1/2 —120 mg QD NCT04505826 · Phase 1/2 33.3%90 mg QD NCT04505826 · Phase 1/2 —90 mg QD NCT04505826 · Phase 1/2 12.1%60 mg QD NCT04505826 · Phase 1/2 —60 mg QD NCT04505826 · Phase 1/2 0%30 mg QD NCT04505826 · Phase 1/2 —30 mg QD NCT04505826 · Phase 1/2 | 4%a NCT05549505 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | show 7 more results | a hot flush 24.8% asthenia 20.8% constipation 15.8% NCT05549505 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Palazestrant
show 7 more results
Vepdegestrant
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Palazestrant's landscape · Vepdegestrant's landscape